{"filings":[{"id":77841,"accession_number":"0001730463-26-000058","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-05-14T11:53:38+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M","event_type":"earnings","confidence":"high","bullets":["Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.","Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.","Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.","Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.","Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95058,"accession_number":"0001193125-26-192362","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings","event_type":"other_material","confidence":"high","bullets":["Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.","Expects total restructuring charges of ~$8M, primarily severance, recognized in H1 2026; plan substantially complete by Q3 2026.","Reaffirms FY 2026 AUCATZYL net product revenue guidance of $120M-$135M, up from $74M in 2025.","Expects ~$15M annualized cost savings beginning in 2027; aims for positive gross margin in 2026.","Clinical programs on track: CATULUS (pediatric ALL), LUMINA (lupus nephritis), BOBCAT (MS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95057,"accession_number":"0001730463-26-000049","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Autolus Therapeutics dismisses EY UK and appoints EY US as independent auditor","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EY UK on April 14, 2026; no disagreements or reportable events in prior two fiscal years.","Audit committee appointed EY US as new independent auditor for FY 2026, effective immediately.","EY UK's audit reports for 2024 and 2025 were unqualified; prior material weakness in internal controls disclosed in Q1 2024 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95056,"accession_number":"0001730463-26-000043","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Autolus hosts ALL Business investor event; presentation lacks specific financial data","event_type":"other_material","confidence":"low","bullets":["Virtual investor event held on April 8, 2026, titled 'Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business'.","Presentation materials posted on company website and attached as Exhibit 99.1 to the 8-K filing.","Filed under Regulation FD; only cover slide and disclaimer visible in the provided exhibit text.","No new material financial, operational, or pipeline details are discernible from the filing content.","Event appears to be a strategic update; no guidance or quantitative disclosures included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107858,"accession_number":"0001730463-26-000032","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.","FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.","FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.","UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.","Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107857,"accession_number":"0001730463-26-000019","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Autolus enters 10-year lentiviral vector supply deal with AGC Biologics","event_type":"other_material","confidence":"high","bullets":["Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.","Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.","AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).","10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.","Agreement replaces prior arrangement; individual work orders govern specific projects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107856,"accession_number":"0001730463-26-000012","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.","FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.","Cash runway extended into Q4 2027 based on current operating plans.","Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.","UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway."],"consensus_eps_estimate":-0.2716,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":75388000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124254,"accession_number":"0001730463-25-000095","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Autolus appoints former BioNTech CSO Ryan Richardson to Board","event_type":"leadership","confidence":"high","bullets":["Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).","Will receive £33,000 annual retainer and initial option grant for 80,000 ADSs at $1.41/ADS, vesting over 36 months.","Richardson led BioNTech's corporate strategy, capital markets, and multiple M&A deals.","Prior roles include Executive Director at J.P. Morgan Healthcare Investment Banking (2011–2018)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124253,"accession_number":"0001730463-25-000081","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).","Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.","FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.","Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.","Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO."],"consensus_eps_estimate":-0.2302,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":51099000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140933,"accession_number":"0001730463-25-000064","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold","event_type":"earnings","confidence":"high","bullets":["Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.","UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.","NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.","Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).","Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025."],"consensus_eps_estimate":-0.2404,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":29905000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158697,"accession_number":"0001730463-25-000046","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Autolus Therapeutics announces results of 2025 Annual General Meeting, all resolutions passed","event_type":"other","confidence":"high","bullets":["Resolution 1 (adopt 2024 accounts): 219,809,664 for, 97,503 against, 477,332 abstain.","Resolution 2 (approve directors' remuneration report): 216,036,710 for, 4,285,817 against.","Resolution 5 (re-elect Dr. R. Iannone as director): 199,042,000 for, 20,750,286 against.","Resolution 7 (approve Employee Share Purchase Plan with 3,000,000 shares): 219,651,874 for, 706,780 against.","All nine ordinary resolutions were duly passed on a poll."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158696,"accession_number":"0001730463-25-000043","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Autolus sets AGM for June 26; two directors to step down; new equity plan proposed","event_type":"other","confidence":"medium","bullets":["AGM on June 26, 2025; resolutions include adoption of 2024 accounts, auditor reappointment (EY LLP), and director re-elections.","Directors Joseph Anderson and Martin Murphy will not stand for re-election, ending their terms after the AGM.","New Employee Share Purchase Plan with Sharesave Sub-Plan (up to 3M shares) approved by Board on May 20, 2025, subject to shareholder approval.","Remuneration report and policy, plus re-election of Dr. Robert Iannone and Dr. Ravi Rao, also on the agenda."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158695,"accession_number":"0001193125-25-132111","cik":1730463,"company_name":"Autolus Therapeutics plc","ticker":"AUTL","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Autolus directors Anderson and Murphy will not stand for re-election at 2025 AGM","event_type":"leadership","confidence":"high","bullets":["Joseph Anderson and Martin Murphy notified the board on May 23, 2025, of their decision.","Both directors stated the decision was not due to any disagreement with management or the board.","Their departure takes effect at the 2025 Annual General Meeting of Shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}